My NCBI Sign In
Jump to: Authorized Access | Attribution | Authorized Requests

Study Description

Technological and scientific advances, stemming in large part from the Human Genome and HapMap projects, have made large-scale, genome-wide investigations feasible and cost-effective. These advances have the potential to dramatically impact drug discovery and development by identifying genetic factors that contribute to variation in disease risk as well as drug pharmacokinetics, treatment efficacy, and adverse drug reactions. In spite of the technological advancements, successful application in biomedical research would be limited without access to suitable sample collections. To facilitate exploratory genetic research, we have assembled a DNA resource from a large number of subjects participating in multiple studies throughout the world. This resource was initially genotyped using the Affymetrix 500K SNP panel. This project includes nearly 6,000 subjects of African American, East Asian, South Asian, Mexican, and European origin.

  • Study Types: Population, Control Set
  • Number of study subjects that have individual level data available through Authorized Access: 5919

Authorized Access
Publicly Available Data (Public ftp)

Connect to the public download site. The site contains release notes and manifests. If available, the site also contains data dictionaries, variable summaries, documents, and truncated analyses.

Study Inclusion/Exclusion Criteria

The POPRES collection includes subjects from ten individual collections. These collections are a mix of unrelated population samples and healthy controls, and are described in Nelson et al. (submitted).

Molecular Data
TypeSourcePlatformNumber of Oligos/SNPsSNP Batch IdComment
Whole Genome Genotyping Affymetrix Mapping250K_Nsp 262264 33767 Affymetrix 500K Set comprises Mapping250K_Nsp and Mapping250K_Sty Arrays
Whole Genome Genotyping Affymetrix Mapping250K_Sty 238304 33766 Affymetrix 500K Set comprises Mapping250K_Nsp and Mapping250K_Sty Arrays
Selected publications
Diseases Related to Study (MESH terms)
Authorized Data Access Requests
Study Attribution
  • POPRES Team Leader
    • Matthew R. Nelson. GlaxoSmithKline, Research Triangle Park, NC, USA
  • CoLaus Principle Investigator (Academia)
    • Gérard Waeber. Department of Internal Medicine, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
  • CoLaus Principle Investigator (Industry)
    • Vincent Mooser. GlaxoSmithKline, Philadelphia, Pennsylvania, USA
  • CoLaus Co-Principle Investigator (Academia)
    • Peter Vollenweider. Department of Internal Medicine, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
  • CoLaus Co-Principle Investigator (Industry)
    • Dawn M. Waterworth. GlaxoSmithKline, Philadelphia, Pennsylvania, USA
  • LOLIPOP Co-Principle Investigators
    • Jaspal S. Kooner. National Heart and Lung Institute, Imperial College London, UK
    • John C. Chambers. Department of Epidemiology and Public Health, Imperial College London, UK
  • African American Controls Co-Principle Investigators
    • Jorge R. Oksenberg. Department of Neurology, University of California, San Francisco, CA, USA
    • Stephen L. Hauser. Department of Neurology, University of California, San Francisco, CA, USA
  • Duke Controls Principle Investigator
    • David B. Goldstein. Center for Population Genomics and Pharmacogenetics, Institute for Genome Sciences and Policy, Duke University, Durham, NC, USA
  • Duke Controls Co-Investigator
    • Anna C. Need. Center for Population Genomics and Pharmacogenetics, Institute for Genome Sciences and Policy, Duke University, Durham, NC, USA